This cancer-fighting biotech sped from startup to IPO filing in 10 months

The company has raised $420 million and its experimental off-the-shelf cell therapy against cancer is in the clinic. But two deaths have been attributed to its headlining drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.